Your Health, We Care
Release date: 2026-04-15 16:30:21 Recommended: 4
Olaparib is an oral prescription medication used to treat certain types of cancer. It is a targeted therapy that works by precisely interfering with the survival pathways of cancer cells. Specifically, olaparib is a poly (ADP-ribose) polymerase inhibitor, or PARP inhibitor. This drug is indicated for various advanced or metastatic cancers, including ovarian cancer, fallopian tube cancer, primary peritoneal cancer, HER2-negative breast cancer, pancreatic cancer, and metastatic castration-resistant prostate cancer. Before use, doctors will conduct specific genetic tests (such as BRCA mutation or HRR gene mutation testing) to determine whether a patient is suitable for treatment with olaparib.
PARP is a protein present in all cells, including cancer cells. Its primary function is to help repair DNA damage within cells, thereby supporting cell survival and growth. In cancer cells, this repair mechanism contributes to continuous tumor proliferation and resistance to chemotherapy. Therefore, it is medically desirable to block PARP's repair activity, causing cancer cells to die from unrepaired DNA damage. Olaparib works by inhibiting the function of the PARP protein to kill cancer cells. It should be noted that healthy cells also contain PARP, so olaparib may have some effects on normal cells, which explains some of its side effects.
Olaparib’s unique mechanism of action is known as the "synthetic lethality" effect. When cancer cells harbor a BRCA gene mutation, their own DNA repair pathway (homologous recombination repair) is already defective. Adding a PARP inhibitor to block another repair pathway leaves the cancer cells unable to repair any DNA damage, ultimately leading to cell death. For cancer cells without BRCA mutations, olaparib may also exert anti-tumor effects by inhibiting PARP activity in combination with other chemotherapy drugs. Clinical trial data show that in patients with metastatic pancreatic cancer carrying hereditary BRCA mutations, olaparib reduced the risk of disease progression or death by 47%, with a median progression‑free survival of 7.4 months, compared to 3.8 months in the placebo group.
